Fatigue after treatment for early stage breast cancer
Open Access
- 19 September 2007
- Vol. 110 (8), 1851-1859
- https://doi.org/10.1002/cncr.22993
Abstract
BACKGROUND. Evidence suggests that fatigue may be a greater problem for cancer survivors than people without cancer. The present study sought to determine whether fatigue was greater in women who had completed treatment for early‐stage breast cancer relative to a demographically matched comparison group of women with no cancer history. METHODS. As part of a larger study, women with stage 0‐II breast cancer were recruited before the start of chemotherapy and radiotherapy (n = 100) or radiotherapy only (n = 121). Fatigue was assessed at the end of treatment and 2, 4, and 6 months later. An age‐ and geographically matched sample of women with no history of cancer was recruited and assessed for comparison purposes. RESULTS. Relative to comparison subjects, breast cancer survivors reported more days of fatigue in the past week at all 4 study assessments (P < .05). These differences appeared to be clinically meaningful in that a greater percentage of patients than nonpatients earned scores in the abnormal range on this measure at each assessment (P < .05). Additional analyses indicated that differences in fatigue between patients and comparison subjects were attributable primarily to heightened fatigue in women who received both chemotherapy and radiotherapy. CONCLUSIONS. Findings suggest that fatigue is a greater problem for breast cancer survivors in the 6 months after completion of chemotherapy than for women with no cancer history. Future research should include longer‐term follow‐up to determine the persistence of fatigue in this population of survivors. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 63 references indexed in Scilit:
- Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injuryFrontiers in Physiology, 2013
- Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarctionJournal of Molecular and Cellular Cardiology, 2012
- Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and postconditioningAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Sensitive Troponin I Assay in Early Diagnosis of Acute Myocardial InfarctionThe New England Journal of Medicine, 2009
- Sphingosine Kinase and Sphingosine 1-Phosphate in CardioprotectionJournal of Cardiovascular Pharmacology, 2009
- Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment.Health Psychology, 2007
- Adult cancer survivors: How are they faring?Cancer, 2005
- Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancerJournal of Pain and Symptom Management, 2004
- Predicting obstructive coronary artery disease with serum sphingosine-1-phosphateAmerican Heart Journal, 2003
- The epidemiology of fatigue and depression: a French primary-care studyPsychological Medicine, 1995